LXRX News and Press, Lexicon Pharmaceuticals Inc. From 09/26/23

INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain THE WOODLANDS, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceut...

2023-09-15 12:55:06 ET Lexicon Pharmaceuticals ( NASDAQ: LXRX ) on Thursday disclosed that President and CFO, Wade Jeffrey bought 10,000 common shares at $1.38 for a transaction value of $13,800.00. Wade Jeffrey now owns 264,381 shares. Over the last 3 months, Insider...

2023-09-15 10:00:12 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25 th Annual Global Investment Conference, taking place September 11-13, 2023. Jeffrey L. Wade, Lexicon’s p...

Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose optimization study planning underway, with initiation of dosing expected before the end of 2023, and extension to run in parallel with...

2023-08-28 08:15:00 ET Summary Lexicon Pharmaceuticals managed to launch Inpefa within 30 days of approval, but it will take at least a few quarters before the success of the commercialization program can be assessed. I expect Lexicon to continue to increase its SG&A spending ...

2023-08-21 17:50:10 ET Summary Lexicon Pharmaceuticals recently gained FDA approval for its heart failure and type 2 diabetes drug, Inpefa, and is marketing the drug aggressively. Lexicon's financials show mixed results, with rising expenses and net loss, but a strong cash positio...

THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heart failure, as well as Lexicon-supported data relating to ...

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of Approximately 50% Demonstrated for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days F...

2023-08-03 22:01:09 ET Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Carrie Siragusa - Vice President of Marketing Lonnel Coats - Chief Executive Officer Jeffrey Wade - President and Chief Fin...